1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Aragon Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Aragon Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 27 pages

Aragon Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Aragon Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Aragon Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Aragon Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Aragon Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Aragon Pharmaceuticals, Inc. - Brief Aragon Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Aragon Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Aragon Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Aragon Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Aragon Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Aragon Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Aragon Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Aragon Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Aragon Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Aragon Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Aragon Pharmaceuticals, Inc. Snapshot 4
Aragon Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Aragon Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Aragon Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Aragon Pharmaceuticals, Inc. - Pipeline Products Glance 9
Aragon Pharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Aragon Pharmaceuticals, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Aragon Pharmaceuticals, Inc. - Drug Profiles 13
ARN-509 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
ARN-810 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
ARN-912 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
SARD Program 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
SERD Program 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Aragon Pharmaceuticals, Inc. - Pipeline Analysis 18
Aragon Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 18
Aragon Pharmaceuticals, Inc. - Pipeline Products By Target 19
Aragon Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 20
Aragon Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 21
Aragon Pharmaceuticals, Inc. - Recent Pipeline Updates 22
Aragon Pharmaceuticals, Inc. - Dormant Projects 24
Aragon Pharmaceuticals, Inc. - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables

Aragon Pharmaceuticals, Inc., Key Information 4
Aragon Pharmaceuticals, Inc., Key Facts 4
Aragon Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Aragon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Aragon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Aragon Pharmaceuticals, Inc. - Phase II, 2013 9
Aragon Pharmaceuticals, Inc. - Phase I, 2013 10
Aragon Pharmaceuticals, Inc. - Preclinical, 2013 11
Aragon Pharmaceuticals, Inc. - Discovery, 2013 12
Aragon Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 18
Aragon Pharmaceuticals, Inc. - Pipeline By Target, 2013 19
Aragon Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 20
Aragon Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 21
Aragon Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 22
Aragon Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 24

List of Figures

Aragon Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Aragon Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Aragon Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Aragon Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.